Clinical Trials Logo

Clinical Trial Summary

RATIONALE: Estrogen can stimulate the growth of cancer cells. Hormone therapy using toremifene may fight the growth of desmoid tumors by reducing the production of estrogen.

PURPOSE: Phase II trial to study the effectiveness of toremifene in treating patients with desmoid tumors.


Clinical Trial Description

OBJECTIVES: I. Determine the efficacy of toremifene in terms of tumor response rate and symptom relief in patients with desmoid tumors. II. Determine the safety of this regimen in these patients. III. Determine the quality of life of patients treated with this regimen.

OUTLINE: Patients are stratified by gender. Patients receive oral toremifene daily until complete or maximal response in the absence of disease progression or unacceptable toxicity. Patients achieving maximal response undergo complete resection of all lesions, if feasible. Nonsurgical candidates with severe or life-threatening disease not achieving partial or complete response or symptom relief at 12 months may continue on toremifene at the discretion of the study chairperson. Patients with stable disease who do not undergo surgery may continue on toremifene for a maximum of 12 months at the discretion of the treating physician. Patients who continue to experience symptom relief at 12 months may continue on toremifene at the discretion of the study chairperson. Quality of life is assessed at baseline and at 2 and 6 months. Patients are followed every 8 weeks for 4 years and then annually thereafter.

PROJECTED ACCRUAL: A total of 24-72 (12-36 per stratum) will be accrued for this study. ;


Study Design

Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00002595
Study type Interventional
Source National Cancer Institute (NCI)
Contact
Status Completed
Phase Phase 2
Start date July 1991
Completion date September 2010

See also
  Status Clinical Trial Phase
Recruiting NCT05561036 - A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor Phase 3
Completed NCT00287846 - Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis Phase 1/Phase 2
Recruiting NCT06258421 - Burden of Disease and Living Situation in Desmoid Patients
Completed NCT00030680 - Radiation Therapy in Treating Patients With Aggressive Fibromatoses Phase 2
Recruiting NCT06081400 - Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting N/A
Active, not recruiting NCT04871282 - A Study of AL102 in Patients With Progressing Desmoid Tumors Phase 2/Phase 3
Recruiting NCT01567046 - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas N/A
Completed NCT01137916 - Study to Evaluate Imatinib in Desmoid Tumors Phase 2
Completed NCT03459469 - Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 Phase 1
Completed NCT06195085 - CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors
Completed NCT01286662 - A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome N/A
Completed NCT01265030 - A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Phase 1/Phase 2
Completed NCT00068419 - Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor Phase 2
Completed NCT04289077 - Quality of Life of Patients With Desmoid-type Fibromatosis
Completed NCT03190174 - Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers Phase 1/Phase 2
Completed NCT00003019 - Vinblastine and Methotrexate in Treating Children With Desmoid Tumors Phase 2
Recruiting NCT05949099 - Study of Cryoablation and Nirogacestat for Desmoid Tumor Phase 2
Active, not recruiting NCT02076906 - MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors Phase 1
Completed NCT00474994 - Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Phase 2
Active, not recruiting NCT03785964 - Nirogacestat for Adults With Desmoid Tumor/Aggressive Fibromatosis (DT/AF) Phase 3